1: Nuralitha S, Siregar JE, Syafruddin D, Roelands J, Verhoef J, Hoepelman AI, Marzuki S. Within-Host Selection of Drug Resistance in a Mouse Model of Repeated Incomplete Malaria Treatment: Comparison between Atovaquone and Pyrimethamine. Antimicrob Agents Chemother. 2015 Oct 26. pii: AAC.00538-15. [Epub ahead of print] doi: 10.1371/journal.pntd.0004068. eCollection 2015 Oct. 3: Dinter D, Gajski G, Domijan AM, Garaj-Vrhovac V. Cytogenetic and oxidative status of human lymphocytes after exposure to clinically relevant concentrations of antimalarial drugs atovaquone and proguanil hydrochloride in vitro. Fundam Clin Pharmacol. 2015 Sep 10. doi: 10.1111/fcp.12153. [Epub ahead of print] doi: 10.1128/AAC.00337-15. Epub 2015 Jun 15. 6: Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kröger N. Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation. Acta Haematol. 2015;134(3):146-54. doi: 10.1159/000380757. Epub 2015 May 5. doi: 10.1128/AAC.00710-15. Epub 2015 Apr 27.